The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against Inogen, Inc.


NEW YORK, March 17, 2015 (GLOBE NEWSWIRE) -- The Brualdi Law Firm, P.C. announces that a lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of Inogen, Inc. ("Inogen" or "the Company") (Nasdaq:INGN) common stock during the period between November 12, 2014 and March 11, 2015 (the "Class Period") for violations of federal securities laws.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased Inogen common stock during the Class Period, and wish to move the court for appointment of lead plaintiff, you must do so by May 12, 2015. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You do not need to seek appointment as a lead plaintiff in order to share in any recovery.

To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact David Titus at The Brualdi Law Firm, P.C. 29 Broadway, Suite 2400, New York, New York 10006, by telephone toll free at (888) 823-9041 or (212) 952-0602, by email to dtitus@brualdilawfirm.com or visit our website at http://www.brualdilawfirm.com.

The Complaint alleges that on March 11, 2015, the Company announced that management discovered potential accounting matters during the first quarter of 2015. This discovery prompted the Audit Committee, with the assistance of independent advisors, to investigate whether any of the Company's accounting policies were violated stemming from these potential accounting matters. The Complaint also alleges that, upon this news, shares of Inogen fell $4.24 per share or over 11% to close at $33.10 per share on March 12, 2015, damaging investors.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.


            

Coordonnées